The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix in chronic non-cancer pain.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Complain of chronic non-cancer pain that persists for >= 3 months

• Pain inadequately controlled by previous treatment with narcotic analgesics (opium or opium-like compounds with potent analgesic effects, eg, tramadol, codeine, morphine, oxycodone)

• Women must be postmenopausal, surgically sterile, abstinent, or practicing an effective method of birth control if they have childbearing potential

• Male patients who agree to use a method of birth control and not to donate sperm for 1 month after the last dose of the study drug

• A written informed consent for study participation

Exclusion Criteria:

• Experience of treatment with Fentanyl matrix within the past 4 weeks

• No previous experience of use of narcotic analgesics

• Past or current history of alcohol or drug abuse

• Cannot use transdermal analgesics due to skin disorder

• Have serious psychiatric disorder and cannot complete overall study procedures and questionnaire in the judgment of the investigator